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Review question
What is the evidence for the physical harms of colorectal cancer screening?
 Objectives: to report the number and types of studies investigating any type of physical harm of colorectal
cancer screening;
to report the types of physical harms of colorectal cancer screening including the risk, magnitude and
consequences of these harms;
to assess and report whether studies have investigated if any factors modify the physical harm of colorectal
cancer screening;
to assess and report the overall quality of the evidence as well as the risk of bias and the adequacy of harm
measurements in studies. 
 
Searches
The search strategy was developed and conducted in cooperation with an information specialist at the
Copenhagen University Library. To maximise the amount of relevant literature retrieved a combination of
index words and keywords was searched. We searched the databases PubMed, MEDLINE, Embase,
CINAHL, PsycINFO and Cochrane Library. All databases were searched from the date from which the
databases have literature coverage until the 12-04-2017. 
We initially developed the search strategy for MEDLINE and subsequently adapted it to the other databases.
We applied no restrictions concerning date, language or study design. The database search will be
supplemented by a targeted grey literature search in Google Scholar. Ongoing trials will be obtained by
searching WHO’s ICTRP Search Portal. 
A preliminary search strategy for MEDLINE is presented in the attached document. We will report the final
literature searches for all databases in the final publication. All studies identified will be compiled in the
reference programme Endnote where duplicates will be removed.
 
Search strategy
https://www.crd.york.ac.uk/PROSPEROFILES/58844_STRATEGY_20170505.pdf
 
Types of study to be included
We will include all types of study designs to promote identification of different types of harms and especially
rare adverse events. The Cochrane Collaboration also recommends this practice, when reviewing studies of
adverse events [3]. Both qualitative and quantitative studies will be included. Articles identified in the search
strategy that do not represent original studies and hence do not report original data like journalism, editorials
etc. will be excluded on title/abstract level. Likewise, systematic reviews will be excluded as they report data
from other studies. We will scrutinize reference lists of systematic reviews deemed relevant to the research
question to identify studies that might be missed in the database searches.
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 3. Loke YK, Price D, and Herxheimer A., Chapter 14: Adverse effects. In: Higgins JPT, Green S (editors). in
Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The
Cochrane Collaboration, 2011. Available from www.cochranehandbook.org.
 
Condition or domain being studied
Colorectal cancer screening is restricted to conventional screening methods as defined under the text box
"Interventions".
The term "screening" covers all aspects of the screening cascade from invitation, primary testing to
downstream diagnostic workup. Harms might occur at any step during the screening cascade [1]. We define
harm as recommended in the PRISMA harms checklist [2]: Harm is the totality of adverse consequences of
screening, being the direct opposite of benefits. Harm, as a term, thereby comprises both complications,
safety issues, adverse events, adverse effects and side effects occurring in relation to screening for
colorectal cancer.
 
1. Harris, R.P., et al., The harms of screening: a proposed taxonomy and application to lung cancer
screening. JAMA Intern Med, 2014. 174(2): p. 281-5.
2. Zorzela, L., et al., PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ, 2016.
352: p. i157.
 
Participants/population
Inclusion: 40 < Age < 80 years, at average risk of colorectal cancer and asymptomatic regarding signs of
colorectal cancer. 
Exclusion: People at higher than average risk of colorectal cancer, including people recruited because of
personal or family history of colorectal cancer, people with known genetic susceptibility, people with earlier or
current diagnosis of colorectal cancer, people with increased risk of colorectal cancer because of illness, for
example inflammatory bowel disorder. 
We will include studies with mixed populations if data and analyses are divided so that data regarding our
target group is available and not mixed in with the data for i.e. symptomatic individuals, colorectal cancer
patients etc. 
 
Intervention(s), exposure(s)
Inclusion: Conventional colorectal cancer screening tools, including any type and combination of the
following: Faecal occult blood test, sigmoidoscopy and colonoscopy. 
Exclusion: Stool testing using in-office digital rectal exam, genetic testing, blood tests, stool DNA tests,
capsule endoscopy or CT colonography. 
 
Comparator(s)/control
Included studies do not need to have a comparator/control group.
 
Context
We will exclude studies taking place in settings that diverge from the normal screening setting to an extent
that comparison with other studies is not meaningful. This exclusion will be on full text level with reasons
noted.
 
Primary outcome(s)
Physical harm. We define harms as any bodily injury or condition. Physical harms are often divided in major
adverse events and other adverse events. We include both types of physical harm. Major adverse events
require medical assistance such as perforation or bleeding due to colonoscopy, anaesthesia complications,
infections, cardiopulmonary complications etc. Other adverse events do not necessarily result in medical
assistance such as discomfort, loss of sleep, physical symptoms due to diagnostic procedures, bloating,
water-electrolyte disturbances etc.
 
Timing and effect measures
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We only include harms which the screening participant experiences. We will exclude studies that report
expected/potential harm to the screening participant. Such studies are excluded on abstract/title level. We
accept any definition of physical harm and any measurement method and timing that does not conflict with
the above-described definition of the physical harm of screening.
 
Secondary outcome(s)
We will assess the adequacy of measurement of harms in studies. We will extract any data or analyses in
studies investigating factors which modify the risk, magnitude or consequences of physical harm.
 
Data extraction (selection and coding)
Study selection process: according to the eligibility criteria defined above two review authors will
independently assess all titles and abstracts of studies identified in the literature searches to identify
potentially eligible studies. Subsequently the full-text of potentially eligible studies will be retrieved. If full text
studies of potentially eligible papers are not available, authors of the studies will be contacted. All full-text
studies retrieved will be independently assessed by two review authors for eligibility. 
Multiple reports of the same study will be linked together when necessary. Disagreements will be resolved by
discussion and if consensus is not reached, a third review author will be consulted to reach agreement. The
main author will assess reference lists of included studies to identify studies relevant to the research
questions that were not identified in the database search. Any study deemed relevant in the reference list
assessment will also be independently assessed by a second review author to ensure objective
inclusion/exclusion.
Once the total number of studies included for review is reached, we will perform a preliminary data extraction
of study details. From the preliminary data extraction we will decide which types of studies to include for
detailed data extraction as described below. The data extraction is divided in this two-step approach to
ensure that studies are comparable so that data can be compared across studies.
The data extraction strategy has been developed using the recommendations in the PRISMA harm checklist
and using a data collection template by the Cochrane Collaboration [4]. 
Data extraction strategy: The data extraction strategy is divided in five categories:
1. Study characteristics
2. Definition of harm(s)
3. Adequacy of the measurements of harms
4. Estimate(s) of harm(s)
5. Potential modifying factors on harms
A standardised pre-defined form will be developed and used to extract data from the included studies. As
non-randomized studies are also included, we expect it will be necessary to revise the data extraction form
during data extraction. All data are extracted by the main author and double-checked by co-authors. Any
disagreements will be discussed until consensus, possibly involving a third review author to reach
agreement.
Data extraction from studies will include: 
1. Study characteristics: - Author, journal, year of publication, funding, study period, study design, information
regarding population, setting and intervention. 
2. Definition of harm(s): - How the harm domain(s) is defined; which types of harm constitute the harm
domain(s). 
3. Adequacy of the measurements of harms
- Who assesses/reports the harm?
- How is the harm measured? Are the measurements performed systematically?
- When is the harm evaluated? Prospectively or retrospectively? Measurements at different time points?
- How are the harms analysed, coded or grouped? Are any simplifications made? 
3. Estimate(s) of harm(s)
- Any estimate of harm. Both qualitative and quantitative data are accepted
Potential modifying factors on harms:
- Are any factors identified as potentially modifying the magnitude, risk or consequence of the physical harm?
- How are those factors modifying the harm estimates assessed?
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If any of the above data is not reported it will be designated as not reported (NR) in data extraction tables.
Reviewers will not be blinded regarding authors and studies when extracting data as this has not been
proved to affect data extraction [5]. 
We will prioritize to include comparative studies and RCTs of colorectal cancer screening. We prioritize these
types of studies because they are the focus of two former Cochrane reviews regarding the benefit and harm
of colorectal cancer screening [6, 7]. The United States Preventive Services Task Force also recently
updated their review about colorectal cancer screening, which also assesses harms of different screening
interventions to some extent [8]. In addition, a third review from the Cochrane Collaboration including harms
of colorectal cancer screening is in the protocol stage. This review focuses on comparing the mortality
reduction of sigmoidoscopy versus colonoscopy [9]. In summary, we have prioritized to include comparative
studies to allow for comparison with existing reviews and to facilitate comparison of harm and harm
assessment to benefit.
 
4. The Cochrane Collaboration. Good practice data extraction form. 21-09-2017]; Available from:
http://epoc.cochrane.org/resources/epoc-resources-review-authors.
 
5. Higgins JPT Deeks JJ (editors), Chapter 7: Selecting studies and collecting data In: Higgins JPT, Green S
(editors),, in Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from www.cochranehandbook.org.
6. Hewitson, P., et al., Cochrane systematic review of colorectal cancer screening using the fecal occult
blood test (hemoccult): an update. Am J Gastroenterol, 2008. 103(6): p. 1541-9.
7. Holme, Ø., et al., Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening
in asymptomatic individuals. Cochrane Database of Systematic Reviews, 2013(9).
8. Bibbins-Domingo, K., et al., Screening for Colorectal Cancer: US Preventive Services Task Force
Recommendation Statement. Jama, 2016. 315(23): p. 2564-2575.
9. Phillips, J., C. Ridd, and K. Thomas, Screening sigmoidoscopy and colonoscopy for reducing colorectal
cancer mortality in asymptomatic persons. Cochrane Database of Systematic Reviews, 2013(9).
 
Risk of bias (quality) assessment
We will assess the risk of bias regarding harm estimates in studies using the Cochrane Collaborations
ROBINS-I tool [10]. We will perform the risk of bias assessment on the study outcome level and not
according to study design. This decision stems from the fact that the definition, measurement and reporting
of harms is heterogeneous and often of poor quality in many clinical studies [3, 11]. In an attempt to account
for the heterogeneity in studies regarding physical harm, we will expand the ROBINS-I tool to include other
types of bias deemed relevant to the review question. The ROBINS-I tool will be altered using reporting
guidelines from the Equator Network and various study quality checklists. We plan to report the altered
ROBINS-I checklist in the final publication. 
The risk of bias assessment will be performed independently by two review authors. Any disagreements will
be discussed until consensus, possibly involving a third review author to reach agreement.
 
3. Loke YK, Price D, and Herxheimer A., Chapter 14: Adverse effects. In: Higgins JPT, Green S (editors). in
Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The
Cochrane Collaboration, 2011. Available from www.cochranehandbook.org.
10. Sterne, J.A.C., et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of
interventions. BMJ, 2016. 355. 11. Ioa nidi , J.P., et al., Better reporting of harms in randomized trials: an extension of the CONSORT
statement. Ann Intern Med, 2004. 141(10): p. 781-8.
 
Strategy for data synthesis
For quantitative data we will calculate summed estimates of harms across studies. These pooled estimates
will be presented via meta analyses using random effect models. Summed estimates will not be calculated in
instances where heterogeneity between studies is deemed too great to allow for meaningful comparisons. In
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these instances harms will be presented by narrative syntheses. 
Using the risk of bias assessment of studies, we expect to perform sensitivity analyses to test how the quality
of studies might affect the aggregate harm estimates.
The harm domain “physical harm” is comprised of different types of harms, i.e. perforation, bleeding, pain
etc. Wherever possible, we will present estimates of the magnitude of each type of harm alongside a GRADE
evaluation of the quality of the evidence. GRADE evaluation of the evidence is performed by the main review
author and double-checked by co-authors. Any disagreements will be discussed until consensus, possibly
involving a third review author to reach agreement.
Zero events: Studies that do not report harms they have assessed or planned to assess are deemed
selective in reporting. Reporting of zero occurrences of a type of harm is noted as a zero event in data
extraction tables. 
 
Analysis of subgroups or subsets
Please view above.
 
Contact details for further information
Frederik Martiny
fhm@sund.ku.dk
 
Organisational affiliation of the review
1) The Section of General Practice and the Research Unit for General Practice in Copenhagen 2) The
Research Unit for General Practice in Region Zealand
1) http://publichealth.ku.dk/sections/general/ 2)
http://www.regionsjaelland.dk/Kampagner/English/Hospitals/Sider/default.aspx
 
Review team members and their organisational affiliations
Mr Frederik Martiny. 1) The Section of General Practice and the Research Unit for General Practice in
Copenhagen 2) The Research Unit for General Practice in Region Zealand
Ms Sigrid Brisson Nielsen. 1) The Section of General Practice and the Research Unit for General Practice in
Copenhagen 2) The Research Unit for General Practice in Region Zealand
Mr Or Rahbek. 1) The Section of General Practice and the Research Unit for General Practice in
Copenhagen 2) The Research Unit for General Practice in Region Zealand
Mr Christian Jauernik. 1) The Section of General Practice and the Research Unit for General Practice in
Copenhagen 2) The Research Unit for General Practice in Region Zealand
Ms Anne Katrine Lykke Bie. 1) The Section of General Practice and the Research Unit for General Practice
in Copenhagen 2) The Research Unit for General Practice in Region Zealand
Professor John Brodersen. 1) The Section of General Practice and the Research Unit for General Practice in
Copenhagen 2) The Research Unit for General Practice in Region Zealand
 
Anticipated or actual start date
02 January 2017
 
Anticipated completion date
29 December 2017
 
Funding sources/sponsors
The Danish Cancer Society Scientific Committee has granted a scholarship of 120.000 DKK to finance the
salary of the main author Frederik Martiny for the year 2017. Grant number R165-A10525-16-S7. The
funding source has no role in the design of this study and will not have any role during its execution,
analyses, interpretation of the data, or decision to submit results.
 
Conflicts of interest
None known
 
                               Page: 5 / 6
 PROSPERO
International prospective register of systematic reviews
Language
English
 
Country
Denmark
 
Stage of review
Review_Ongoing
 
Subject index terms status
Subject indexing assigned by CRD
 
Subject index terms
Colorectal Neoplasms; Humans; Occult Blood
 
Date of registration in PROSPERO
03 November 2017
 
Date of publication of this version
22 September 2017
 
Details of any existing review of the same topic by the same authors
 
Stage of review at time of this submission
 
Stage Started Completed
Preliminary searches Yes Yes
Piloting of the study selection process Yes Yes
Formal screening of search results against eligibility criteria Yes No
Data extraction No No
Risk of bias (quality) assessment No No
Data analysis No No
 
Versions
 
22 September 2017
PROSPERO
This information has been provided by the named contact for this review. CRD has accepted this information in good
faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration
record, any associated files or external websites. 
Powered by TCPDF (www.tcpdf.org)
                               Page: 6 / 6
